• Mashup Score: 2

    e19513 Background: Patients (Pts) with hematologic malignancies (HM) are at greater risk of severe morbidity and mortality caused by COVID19 and show a lower response to the two-dose COVID19 mRNA vaccine series. The primary vaccine series now includes a third dose of the COVID19 vaccine (3V) for immunocompromised Pts. The objective of this study was to explore the characteristics of HM patients who had no change in SARS-CoV-2 spike protein titer levels post 3V (-/-) to gain a better understanding of the drivers of serostatus. Methods: This retrospective cohort study analyzed Pt data on SARS-CoV-2 spike IgG antibody titers pre- and post- 3V across the healthcare system. This study included 268 fully vaccinated HM Pts diagnosed with HM between October 31, 2019 and January 31, 2022 and had a negative serostatus prior to 3V. Post 3V titers were obtained 21 days after 3V. Demographics, association between characteristics and seroconversion status, and odds ratios were all assessed (table).

    Tweet Tweets with this article
    • Characteristics of Pts w/ hematologic malignancies w/o seroconversion post-#COVID19 3rd vaccine dosing (3V): Real-world data from large midwestern healthcare system [Jun 2, 2022] Hallmeyer et al. @JimW9200 Abstract e19513 #ASCO22 https://t.co/22Q2IGyWHE #COVID19Vaccine #IDonc https://t.co/YwhB2jYEUC

  • Mashup Score: 1

    1530 Background: In a prior analysis, we identified 525 pts with newly diagnosed NSCLC 4 harboring AOD in the ICD. Of these, 141 were treated prior to the reporting of AOD with chemotherapy (C), immune checkpoint inhibitor (ICI), or both. This report details the clinical outcomes of these 141 compared to the 384 treated after AOD reported. Methods: Real world data (RWD) were obtained from a curated ICD for pts with NSCLC 4 diagnosed 1/1/2018-12/31/2020 with cutoff of data 3/31/2021. Pts with EGFR, ALK, ROS1, BRAF, MET, RET, HER2, and NTRK were included if their treatment record were captured. Also included were demographics, ECOG score, date of first report of AOD and dates of initiations of first and any second line of therapy and date of apparent death (AD). Outcome measures were time to next treatment or apparent death (TTNT) and apparent survival (AS) (ICD model does not allow date of death per HIPAA de-identified Expert Determination). Descriptive statistics were used with Kaplan-

    Tweet Tweets with this article
    • Outcomes in Pts w/ stage 4 NSCLC harboring actionable oncogenic drivers when treated prior to report of mutation w/o TKIs: An Integra Connect Database (ICD) retro obs study - Smith et al. #ASCO22 Abs 1530 https://t.co/D6pzKQqQ7Y #lcsm #PrecisionMedicine https://t.co/e9dxAeC4mw

  • Mashup Score: 0

    AuthorsChristine HoRoswell Park Comprehensive Cancer Center, Buffalo, NYChristine Ho, Paul K. Wallace, Kristopher Attwood, Sarah Parker, Hemn Mohammadpour, Megan Herr, George Chen, Joseph Tario, Philip L. McCarthy, Jens HillengassOrganizationsRoswell Park Comprehensive Cancer Center, Buffalo, NY, Roswell Park Comprehensive Cancer Center, Transplant and Cellular Therapy Program, Department of…

    Tweet Tweets with this article
    • Immune cell differences between patients in different stages of monoclonal plasma cell disorders - Ho et al. #ASCO22 Abstract 8065 https://t.co/TsSdwNPcLr #ImmunoOnc #mmsm https://t.co/5M0Vghq7hX

  • Mashup Score: 2

    “Seeing a drug emerge is one of the most exciting things that you can do,” said AstraZeneca’s Susan Galbraith. “And then seeing that other people start to see it in that way. That’s a very exciting moment.” #ASCO23

    Tweet Tweets with this article
    • I took a look at how AstraZeneca came to rule #ASCO23. And #ASCO22. And ‘21. And ‘20. A story of persistence in cancer drug development. $azn https://t.co/TEhAS9KUtq

  • Mashup Score: 6

    Saturday June 3 · 6:00 PM – 7:30 PM Central Daylight Time (CDT). The TAP       Hyatt Regency McCormick Place 2233 S Martin Luther King DrChicago, IL 60616 Join us as we celebrate the movers, shakers and industry-name-makers at this prestigious awards ceremony hosted by Healio | HemOnc Today. The Disruptive Innovators awards will span across nine…

    Tweet Tweets with this article
    • I’m dusting off my @GoHealio #ASCO22 “patient voice” award for #ASCO23 and excited to see which #patientAdvocate group received this #DisruptiveInnovators award at the ceremony Saturday night. There’s still time to RSVP: https://t.co/I05DOXz2dE https://t.co/HKfXvENQRX

  • Mashup Score: 1

    AuthorsJuan DuShanghai Changzheng Hospital, Shanghai, Shanghai, ChinaJuan Du, Wei-Jun Fu, Hua Jiang, Baoxia Dong, Li Gao, Li Liu, Jian Ge, Aili He, Lu Li, Jing Lu, Xiequn Chen, Jia Liu, Qi Zhang, Jiaping He, Lianjun Shen, Lihong Weng, Hua Zhang, Wei Cao, Wenling LiOrganizationsShanghai Changzheng Hospital, Shanghai, Shanghai, China, Shanghai Changzheng Hospital, Shanghai, China, Xijing Hospital,…

    Tweet Tweets with this article
    • #mmsm #ASCO23 BCMA/CD19 dual-targeting CAR-T ➡️ https://t.co/IGPKsiG4GS 🛑presented #ASCO22 #ASH22 ✅continue to show some promise with high ORR , MRD-ve but I am concerned about presenting this every few months with few more pts(n=29) ✅median: DOR:37 mo,PFS:38 mo https://t.co/KmFARjgjdp

  • Mashup Score: 0

    The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology

    Tweet Tweets with this article
    • Want a recap on what makes #ASCO23 so exciting? Visit https://t.co/qH0bG8agF6 to check out our coverage of last year’s #ASCO22 to get you into the spirit, and ready to join us for this year! @VJOncology @ASCO #ASCO23 #Cancer #OncTwitter #MedTwitter https://t.co/3IgrvTFqYR

  • Mashup Score: 0

    AuthorsChristine HoRoswell Park Comprehensive Cancer Center, Buffalo, NYChristine Ho, Paul K. Wallace, Kristopher Attwood, Sarah Parker, Hemn Mohammadpour, Megan Herr, George Chen, Joseph Tario, Philip L. McCarthy, Jens HillengassOrganizationsRoswell Park Comprehensive Cancer Center, Buffalo, NY, Roswell Park Comprehensive Cancer Center, Transplant and Cellular Therapy Program, Department of…

    Tweet Tweets with this article
    • Immune cell differences between patients in different stages of monoclonal plasma cell disorders - Ho et al. #ASCO22 Abstract 8065 https://t.co/TsSdwNPcLr #ImmunoOnc #mmsm https://t.co/BVdZJLOtjm

  • Mashup Score: 0

    DCISionRT: Assessing Breast Cancer Adjuvant Endocrine Therapy After BCS Chirag Shah MD By Chirag Shah, MD So this study was an analysis of 926 patients who had undergone breast conserving surgery, with or without radiation therapy and with or without endocrine therapy. They were diagnosed with ductal carcinoma in si…

    Tweet Tweets with this article
    • 🥼 Dr. Chirag Shah discusses the use of DcisionRT for assessing adjuvant endocrine therapy for breast cancer after breast-conserving surgery. Watch and Share the Video Here: https://t.co/fzyfsRNKOl @CShahMD @ClevelandClinic #ASCO22 #BreastCancer https://t.co/MFPWVOcygJ